SecBot SecBot
8-K ·Filed Jul 29, 2026

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
MIXED
Impact 5/10
Horizonweeks Processed3mo ago SEC0001171843-26-004974
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor the H2 ramp implied by maintained full-year EPS guidance ($1.91-$2.11) given Q1 non-GAAP EPS of $0.53 and Q2 of $0.02. The innovative brand growth trajectory (43% LC YoY) and raised brand outlook suggest underlying business momentum. Key catalysts: olanzapine LAI launch in Q4 2026, duvakitug Phase 3 updates, and the NYSE direct listing in September. The generics erosion (especially lenalidomide) remains a headwind to watch.

DirectionMixed
Confidencehigh
Horizonweeks

Drugs in focus

TEVA drug pipeline →

AUSTEDO

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already on the market — first approved April 2017; Austedo XR approved February 2023
Next catalyst
None dated

What to watchAustedo is a mature, approved revenue driver for Teva, commercial execution and growth trajectory matter more than any single catalyst. Watch Teva's quarterly innovative brand revenue growth rate (43% LC YoY in H1 2026) and any label-expansion trial updates for downward drift potential, as the binary approval catalysts are years past.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$34.71
T+0 close · Jul 29, 2026 · via day close
Latest settled
+15.85%
T+60 · $40.21
Vs SPY
+11.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $34.71entry
  2. T+1 · 4mo ago +2.02%α +0.34% · $35.41
  3. T+5 · 3mo ago +0.03%α −5.50% · $34.72
  4. T+20 · 3mo ago +9.25%α +4.23% · $37.92
  5. T+60 · 26d ago +15.85%α +11.12% · $40.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teva reported Q2 2026 revenue of $4.14B (-1% YoY) and non-GAAP EPS of $0.02, both below consensus ($0.05). The headline GAAP loss of $0.49/share was driven by a $726M Emalex acquisition charge ($724M IPR&D). However, key innovative brands (AUSTEDO, AJOVY, UZEDY) collectively grew 43% YoY in local currency to over $1B, and the company raised its 2026 revenue outlook for all three brands. Full-year non-GAAP EPS guidance of $1.91-$2.11 was maintained, implying a strong H2 ramp. A credit rating upgrade to investment-grade BBB- by Fitch and the planned ADS-to-direct-listing conversion add to the positive narrative.

Key Financial Metrics

EPS
$0.02
est $0.05 · -60.0%
Revenue
$4.1B
-0.8% YoY
Rating
in line
Guidance
$16.5 - $16.85 billion
raised
Free Cash Flow
$622.0M
Gross Margin
52%

Key Facts

  • Q2 2026 revenue $4,142M, down 1% YoY ($4,176M) and 3% in local currency
  • GAAP loss per share $0.49 vs $0.24 EPS in Q2 2025; includes $726M Emalex-related expenses
  • Non-GAAP diluted EPS $0.02 vs $0.66 a year ago, also impacted by ($0.61)/share from Emalex
  • Key innovative brands (AUSTEDO $696M, AJOVY $244M, UZEDY $77M) grew 43% LC YoY; 2026 revenue outlook raised to ~$3.7B combined
  • Full-year 2026 guidance maintained: revenue $16.5-$16.85B, non-GAAP EPS $1.91-$2.11, FCF $2.0-$2.4B
  • Fitch upgraded corporate credit rating to investment grade BBB-
  • ADS program replaced with direct listing of ordinary shares on NYSE, effective September 14, 2026
  • Emalex acquisition closed (ecopipam NDA submitted); pipeline advancing: duvakitug, olanzapine LAI, TEV-408
  • Operating cash flow $411M, free cash flow $622M; debt $16.6B, leverage 68%
  • Legal settlements and loss contingencies of $230M in Q2, including $117M antitrust provision and $49M opioid update

Financial Impact

Q2 revenue $4.14B vs consensus $4.03B (beat implied); non-GAAP EPS $0.02 vs consensus $0.05 (miss). GAAP loss $0.49 vs $0.24 EPS last year. Full-year guidance maintained.

revenueepsgaap-lossnon-gaap-epscash-flowdebt

Risk Factors

  • Generics revenue decline (U.S. segment -31% YoY for generics) due to lenalidomide competition may persist
  • Emalex integration costs and IPR&D charges could pressure near-term margins
  • Legal exposure: opioid settlements and antitrust litigation provisions remain elevated ($230M in Q2)
  • Foreign exchange volatility ($85M positive impact in Q2, but swings can be unpredictable)
  • High debt load ($16.6B) with 68% leverage and 27% of debt maturing short-term

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-004974
Document: f8k_072926.htm0001171843-26-004974
Document: 0001171843-26-004974-index-headers.html0001171843-26-004974
Document: 0001171843-26-004974-index.html0001171843-26-004974
Document: 0001171843-26-004974.txt0001171843-26-004974
8-K Data (Synthetic)0001171843-26-004974

Track record

61 reports on TEVA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens Wed (10h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026